About: Review of Viral Testing (Polymerase Chain Reaction) and Antibody/Serology Testing for Severe Acute Respiratory Syndrome-Coronavirus-2 for the Intensivist

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Review of Viral Testing (Polymerase Chain Reaction) and Antibody/Serology Testing for Severe Acute Respiratory Syndrome-Coronavirus-2 for the Intensivist Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Review of Viral Testing (Polymerase Chain Reaction) and Antibody/Serology Testing for Severe Acute Respiratory Syndrome-Coronavirus-2 for the Intensivist
Creator	Bennett-Guerrero, Elliott Fries, Bettina Motley, Michael Spitzer, Eric
topic	covid:b85cd82d242ec898a2b1c066f1ee363a76657b80#this
Source	Medline; PMC
abstract	OBJECTIVE: As the severe acute respiratory syndrome-coronavirus-2 pandemic develops, assays to detect the virus and infection caused by it are needed for diagnosis and management. To describe to clinicians how each assay is performed, what each assay detects, and the benefits and limitations of each assay. DATA SOURCES: Published literature and internet. STUDY SELECTION: As well done, relevant and recent as possible. DATA EXTRACTION: Sources were read to extract data from them. DATA SYNTHESIS: Was synthesized by all coauthors. CONCLUSIONS: Available assays test for current or previous severe acute respiratory syndrome-coronavirus-2 infection. Nucleic acid assays such as quantitative, or real-time, polymerase chain reaction and loop-mediated isothermal amplification are ideal for acute diagnosis with polymerase chain reaction testing remaining the “gold standard” to diagnose acute infection by severe acute respiratory syndrome-coronavirus-2, specifically the presence of viral RNA. Assays that detect serum antibodies can theoretically diagnose both acute and remote infection but require time for the patient to develop immunity and may detect nonspecific antibodies. Antibody assays that quantitatively measure neutralizing antibodies are needed to test efficacy of convalescent plasma therapy but are more specialized.
has issue date	2020-06-15(xsd:dateTime)
bibo:doi	10.1097/cce.0000000000000154
bibo:pmid	32696013
has license	cc-by-nc-nd
sha1sum (hex)	b85cd82d242ec898a2b1c066f1ee363a76657b80
schema:url	https://doi.org/10.1097/cce.0000000000000154
resource representing a document's title	Review of Viral Testing (Polymerase Chain Reaction) and Antibody/Serology Testing for Severe Acute Respiratory Syndrome-Coronavirus-2 for the Intensivist
has PubMed Central identifier	PMC7314351
has PubMed identifier	32696013
schema:publication	Crit Care Explor
resource representing a document's body	covid:b85cd82d242ec898a2b1c066f1ee363a76657b80#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/b85cd82d242ec898a2b1c066f1ee363a76657b80
is schema:about of	named entity 'infection' named entity 'severe' named entity 'Severe Acute Respiratory Syndrome' named entity 'INFECTION' named entity 'detect' named entity 'diagnosis' named entity 'severe acute respiratory syndrome' named entity 'infection' named entity 'Critical Care' named entity 'Intensivist' named entity 'Critical Care' named entity 'Severe Acute Respiratory Syndrome' named entity 'Biohazard' named entity 'PCR' named entity 'infection' named entity 'viral culture' named entity 'viral RNA' named entity 'SARS-CoV-2' named entity 'nasopharyngeal swab' named entity 'increases exponentially' named entity 'colloidal gold' named entity 'finger prick' named entity 'genetic modification' named entity 'reference method' named entity 'virus' named entity '229E' named entity 'NL63' named entity 'IgM' named entity 'SARS-CoV-2 virus' named entity 'protein' named entity 'outpatient settings' named entity 'coronavirus disease 2019' named entity 'infection' named entity '95%' named entity 'linear correlation' named entity 'Red arrows' named entity 'serum' named entity 'viral genome' named entity 'serology tests' named entity 'infection' named entity 'serum' named entity 'logarithm' named entity 'vaccines' named entity 'virion membrane' named entity 'microscopy' named entity 'amino acids' named entity 'qPCR' named entity 'cell culture' named entity 'coronaviruses' named entity 'IgG antibodies' named entity 'semilog' named entity 'ELISAs' named entity 'plasma' named entity 'Nucleocapsid' named entity 'titer' named entity 'ACE2' named entity 'FDA' named entity 'SARS-CoV' named entity 'viruses' named entity 'ACE2' named entity 'fluorescent' named entity 'antigen' named entity 'virus' named entity 'Sarbecovirus' named entity 'viral load' named entity 'antibody' named entity 'SARS-CoV-2' named entity 'SARS-Cov-2' named entity 'infection' named entity 'RBD' named entity 'PCR tests' named entity 'viruses' named entity 'Virus' named entity 'viral RNA' named entity 'seropositive' named entity 'serum'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software